



For further information:
Investor Relations (Tel: +34 91 244 44 22)
Marta Campos Martínez mcampos@rovi.es

ROVI announces the agreement to market Volutsa[®] in Spain

Madrid, 11 February 2015 – Laboratorios Farmacéuticos Rovi, S.A. (ROVI) announces it has signed an agreement with Astellas Pharma, S.A. (Astellas) to market Volutsa[®] (solifenacin succinate and tamsulosin hydrochloride) in Spain, which corresponds to Astellas' Vesomni[®] product.

Under the terms of this marketing agreement, ROVI will undertake the promotion and distribution in Spain of Volutsa[®], a modified release tablet containing two active substances, solifenacin and tamsulosin. Solifenacin is an anticholinergic drug and tamsulosin belongs to a drugs group called alpha-antagonists. Volutsa[®] is indicated for the treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men who are not adequately responding to treatment with monotherapy.

When the prostate becomes enlarged, urinary problems (voiding symptoms) such as urinary hesitancy (difficulty to initiate urination), reduction of the flow of urine (weak stream), urine leakage and sensation of incomplete emptying of the bladder, may occur. At the same time, the bladder may also be affected and it contracts spontaneously at times when urination is delayed. This causes bladder (storage) symptoms such as changes in the sensation of the bladder, urgency (having an uncontrollable urge to urinate) and a high urinary frequency to occur. Solifenacin reduces involuntary contractions of the bladder and increases the amount of urine that the bladder can hold. Tamsulosin allows the urine to pass more easily through the urethra, thereby facilitating urination.

ROVI has started to market Volutsa[®] in the first quarter of 2015, at the same time Astellas has started commercialising Vesomni[®].